VIVASC THERAPEUTICS
Vivasc Therapeutics is a drug development company. They offer services that include drug development, cardiology, atrial fibrillation, and AFiB.
VIVASC THERAPEUTICS
Industry:
Biotechnology Health Care Medical Pharmaceutical
Founded:
2019-01-01
Address:
Pittsburgh, Pennsylvania, United States
Country:
United States
Website Url:
http://www.vivasctherapeutics.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
284 K USD
Technology used in webpage:
Euro U.S. Server Location
Similar Organizations
Asofarma
Asofarma is a pharmaceutical company that specializes in the development, production, and marketing of products for human use.
Pharmarket
Pharmarket is startup Health Tech that connects buyers and providers of the pharma field.
Current Employees Featured
Investors List
National Heart, Lung and Blood Institute
National Heart, Lung and Blood Institute investment in Grant - Vivasc Therapeutics
Official Site Inspections
http://www.vivasctherapeutics.com
- Host name: 36.0.153.160.host.secureserver.net
- IP address: 160.153.0.36
- Location: Scottsdale United States
- Latitude: 33.6013
- Longitude: -111.8867
- Metro Code: 753
- Timezone: America/Phoenix
- Postal: 85260
More informations about "Vivasc Therapeutics"
Vivasc Therapeutics - Crunchbase Company Profile & Funding
Contact Email [email protected] Vivasc Therapeutics is a drug development company. They offer services that include drug development, cardiology, atrial fibrillation, and …See details»
Vivasc Therapeutics Inc. Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Vivasc Therapeutics Inc. of Pittsburgh, PA. Get the latest business insights from Dun & Bradstreet.See details»
Vivasc Therapeutics 2025 Company Profile: Valuation, …
Vivasc Therapeutics General Information Description. Developer of a medicinal drug platform designed to treat cardiac problems. The company's platform develops pre-clinical cardiac drugs utilizing the proprietary cardiac targeting …See details»
Vivasc Therapeutics - Company Contact Details | Seamless.AI
Vivasc Therapeutics is an early stage, pre-clinical cardiac drug development company. We are utilizing the proprietary Cardiac Targeting Peptide (CTP) platform technology to deliver various …See details»
Vivasc Therapeutics overview - services, products, equipment data …
Vivasctherapeutics.com. 2403 Sidney St Suite 255 Pittsburgh, Pennsylvania 15203, US. linkedin. Vivasc Therapeutics. Vivasc Therapeutics is an early stage, pre-clinical cardiac drug …See details»
Vivasc Therapeutics - Products, Competitors, Financials, Employees ...
Vivasctherapeutics.com. Overview & Products; Financials; People; Stage Grant - II | Alive. Total Raised $610K. Last Raised $280K | 2 yrs ago. About Vivasc Therapeutics. Vivasc …See details»
VIVASC THERAPEUTICS INC. - Drug pipelines, Patents, Clinical …
Vivasctherapeutics.com. Private Company | 2019 | Pennsylvania, United States | 10-50 | vivasctherapeutics.com. Last update 07 Mar 2025. Overview. Pipeline. Deal. Translational …See details»
Vivasc Therapeutics - Overview, News & Similar companies
Www.vivasctherapeutics.com. Revenue $8.4 Million. Industry Manufacturing General Manufacturing . Recent News & Media. Vivasc Therapeutics Inc. Receives Its Second NIH …See details»
Vivasc Therapeutics - VentureRadar
Website: https://vivasctherapeutics.com/ Develops a proprietary Cardiac Targeting Peptide platform technology that enables targeted delivery of diverse cargo to ...See details»
Vivasc Therapeutics - Craft
Vivasc Therapeutics is an early stage, pre-clinical cardiac drug development company. It utilizes a proprietary Cardiac Targeting Peptide (CTP) platform technology.See details»
Vivasc Therapeutics - 2025 Company Profile - Tracxn
Apr 4, 2025 Dyt.club-Ajmer based, 2023 founded, Unfunded company; Ari-Turkey based, 1989 founded, Unfunded company; Arcon Armaturen & Components-Austria based, 1992 founded,. …See details»
VIVASC THERAPEUTICS INC Pittsburgh PA, 15203 - Company …
Free Business profile for VIVASC THERAPEUTICS INC at 2403 Sidney St, Pittsburgh, PA, 15203-2194, US.See details»
Vivasc Therapeutics - Company Profile & Staff Directory
Vivasc Therapeutics is an early stage, pre-clinical cardiac drug development company. We are utilizing the proprietary Cardiac Targeting Peptide (CTP) platform technology to deliver various …See details»
Vivasc Therapeutics: Drug pipelines, Patents, Clinical trials - Synapse
Nov 14, 2023 Explore Vivasc Therapeutics with its drug pipeline, therapeutic area, technology platform, , Technology Platform:miRNA, Small molecule drug, Drug:CTP-miRNA, CTP-Amio.See details»
Vivasc Therapeutics, Inc. | Life Sciences PA - Default Site
Www.vivasctherapeutics.com; About. Vivasc Therapeutics is an early stage, pre-clinical cardiac drug development company. We are utilizing the proprietary Cardiac Targeting Peptide (CTP) …See details»
VIVASC THERAPEUTICS INC. - CAGE.report
VIVASC THERAPEUTICS INC. CAGE CODE 896T5. Vivasc Therapeutics Inc. has a registered in the System for Award Management for doing business with and bidding for contracts by the …See details»
Vivasc Therapeutics Inc. Receives NIH Phase I STTR ... - Business Wire
Jul 15, 2020 Matthew Captline, Executive Vice President of Operations Phone: +1-412-818-9908 Email: [email protected]. Site Navigation. Home. Home; Submit a Press …See details»
Vivasc Therapeutics - VentureRadar
Similar Companies: TAHO Pharmaceuticals Ltd. Taiwan Privately Held Taihe Biotech Pharmaceutical Co., Ltd. is a biotechnology new drug development company, which is a …See details»
Vivasc Therapeutics Inc. Receives Its Second NIH Phase I STTR …
Oct 19, 2022 PITTSBURGH--(BUSINESS WIRE)--Vivasc Therapeutics Inc. is pleased to announce it has initiated its second NIH Phase I STTR research grant (Award Number …See details»
Vivasc Therapeutics Awarded NIH PHI STTR - Innovation …
May 15, 2024 8/18/22 Receives NIH Ph I STTR Grant to Utilize Novel Cardiac Targeting Peptides for Targeted Delivery of Amiodarone to the Heart for Treatment of Atrial Fibrillation This approach may minimize systemic toxicity associated with amiodarone The University of Pittsburgh and Vivasc Therapeutics Inc. has been awarded a PHI STTR grant by the NIH National Heart,...See details»